Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: January 21, 2010
Last updated: February 14, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2012
  Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)